$LSTA

LISATA THERAPEUTICS, INC.

Lisata Therapeutics is a clinical-stage pharmaceutical company that develops therapies for solid tumors and other serious diseases. Its investigational product, certepetide, is designed to help anti-cancer drugs penetrate solid tumors and to modify the tumor microenvironment. Lisata studies certepetide in combination with chemotherapy and immunotherapy across cancer types including pancreatic, bile duct, colon, appendiceal and brain cancers. It also seeks collaborations with developers of cancer drugs and diagnostic agents to apply its CendR Platform®. Lisata’s business focuses on discovering, developing and commercializing therapies, with certepetide in clinical trials and no marketed product identified. Its principal executive offices are in Basking Ridge, New Jersey.

No enriched coverage for $LSTA in the last 7 days.

No SEC Form 4 filings for $LSTA in the last 30 days.

See all $LSTA insider activity →
Low

LISATA THERAPEUTICS, INC. (LSTA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

LISATA THERAPEUTICS, INC. (LSTA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 9, 2026, Lisata Therapeutics, Inc. (the “ Company ”) held its 2026 annual meeting of stockholders (the “ Annual

Lisata subsidiary Marea Therapeutics reports up to 72% triglyceride reduction in Phase 2b trial

Lisata Therapeutics' subsidiary Marea reported that its experimental antibody MAR001 reduced triglycerides by up to 72.2% in a Phase 2b trial, meeting all objectives. The trial involved 235 adults with severe hypertriglyceridemia. MAR001 also reduced remnant cholesterol and showed a safety profile comparable to placebo. Marea has started Part B of the trial and is developing a longer-acting version, MAR005.

MARKETS LIVE: Wall Street closes higher as Dow jumps 556 points, tech stocks lag

Wall Street closed higher with the Dow Jones up 1.1% (556 points) to 52,178, while the S&P 500 and Nasdaq gained 0.3% and 0.1% respectively. Tech stocks lagged due to AI development cost concerns. CoreWeave rebounded 10% after early losses. Bank of America upgraded CarMax to 'buy' with a $65 target. Ericsson rose 9% on strong Q3 sales growth, and Taiwan Semiconductor reported a 69% net income increase.

LSTA sentiment & insider activity

Recent LSTA coverage spans corporate actions, financial news and mergers & acquisitions.

What's driving LSTA

AlphAI scores every news story that mentions LSTA with an AI model for sentiment and relevance, and aggregates insider trades from LISATA THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $LSTA

Score
$LSTALowShareholder vote

LISATA THERAPEUTICS, INC. (LSTA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

LISATA THERAPEUTICS, INC. (LSTA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 9, 2026, Lisata Therapeutics, Inc. (the “ Company ”) held its 2026 annual meeting of stockholders (the “ Annual

Lisata subsidiary Marea Therapeutics reports up to 72% triglyceride reduction in Phase 2b trial

Lisata Therapeutics' subsidiary Marea reported that its experimental antibody MAR001 reduced triglycerides by up to 72.2% in a Phase 2b trial, meeting all objectives. The trial involved 235 adults with severe hypertriglyceridemia. MAR001 also reduced remnant cholesterol and showed a safety profile comparable to placebo. Marea has started Part B of the trial and is developing a longer-acting version, MAR005.

MARKETS LIVE: Wall Street closes higher as Dow jumps 556 points, tech stocks lag

Wall Street closed higher with the Dow Jones up 1.1% (556 points) to 52,178, while the S&P 500 and Nasdaq gained 0.3% and 0.1% respectively. Tech stocks lagged due to AI development cost concerns. CoreWeave rebounded 10% after early losses. Bank of America upgraded CarMax to 'buy' with a $65 target. Ericsson rose 9% on strong Q3 sales growth, and Taiwan Semiconductor reported a 69% net income increase.

$LSTALowExec change· appointed

LISATA THERAPEUTICS, INC. (LSTA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

LISATA THERAPEUTICS, INC. (LSTA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Lisata Therapeutics Appoints Jeff Farrow to Board of Directors Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee Liberty Corner, N.J., October 14, 2026 - Li

Lisata Therapeutics wins new US patent for pancreatic cancer drug

Lisata Therapeutics (LSTA) received a new US patent for its drug certepetide, covering its use with anti-cancer agents to treat pancreatic cancer and other solid tumors. The patent expires in 2041, with market exclusivity until 2043. The company claims certepetide enhances drug delivery and tumor susceptibility to immunotherapies, showing promising safety and efficacy in trials.

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

Marea Therapeutics, a subsidiary of Lisata Therapeutics (LSTA), dosed the first patient in a Phase 2 trial of MAR002 for acromegaly. MAR002 is a potential best-in-class therapy that may enable dosing as infrequently as once every two weeks. The trial aims to enroll 72 participants, with a primary endpoint of IGF-1 reduction after 10 weeks of treatment.

Lisata Therapeutics (LSTA) Buys Marea and Signs $225M Financing. Is the Dilution Worth it?

Lisata Therapeutics (LSTA) acquired Marea Therapeutics and secured $225M in financing, diluting legacy shareholders to 2.39% ownership. The funds will support operations into 2028, covering clinical trials for severe hypertriglyceridemia and acromegaly. Success could attract partnerships or improve future financing terms, but risks include clinical trial failures and cash settlement obligations.

$LSTAHighAI 9/10

Lisata and Aethlon close reverse merger deals

Lisata Therapeutics acquired Marea Therapeutics in a stock-for-stock deal with a $225M private placement, gaining access to Marea's cardioendocrine pipeline. Aethlon Medical merged with North Immunology in an all-stock deal with a $180M private placement, focusing on NOR-101 for atopic dermatitis. Both deals aim to advance pipelines and create value for shareholders.

Related tickers